#USA #New York #Class Action #The Gross Law Firm #Cardlytics

Cardlytics Shareholders: Join the Class Action Suit for Recovery

The Gross Law Firm has issued a significant announcement urging shareholders of Cardlytics, Inc. (NASDAQ: CDLX) to consider joining a class action lawsuit seeking financial recovery. If you purchased shares of Cardlytics during the specified class period, it's critical to take action now.

Key Details of the Class Action

The class action lawsuit targets shareholders who acquired Cardlytics shares from March 14, 2024, to August 7, 2024. During this time, several allegations arose regarding misleading statements made by the company that influenced stock prices and investor decisions. As a shareholder, you are encouraged to communicate with The Gross Law Firm for a potential lead plaintiff appointment; however, this appointment isn’t mandatory for participation in the recovery process.

What Are the Allegations?

Several serious allegations underpin the class action suit against Cardlytics. It is claimed that during the class period, the company issued materially false and/or misleading information, falling short of necessary disclosures on multiple fronts:
1. Consumer Engagement Benefits Misrepresented: Cardlytics allegedly did not properly disclose that increased consumer engagement caused a rise in consumer incentives, suggesting an optimistic view not grounded in reality.
2. Failure to Match Billings with Engagement: The company purportedly failed to align its billings with the increases in consumer engagement, exposing a significant disconnect that could impact revenue.
3. Risk of Revenue Declines: Given the lack of transparency, there was raised concern that revenue growth could taper off or decline, which was not communicated to investors.
4. Impact of Changes in Ads Decision Engine: Adjustments to the Ads Decision Engine, which were intended to boost engagement, inadvertently created under-delivery of budgets and billing estimates for customers, raising further concerns regarding business viability.
5. Misleading Optimism: Overall, positive statements made by company executives about the business's prospects were alleged to be materially misleading and lacked a solid factual basis.

Urgent Deadline for Shareholders

For those who have experienced financial setbacks due to these alleged missteps, time is of the essence. The deadline for registration as a lead plaintiff is March 25, 2025. Hence, you should not delay in securing your position in this important case.

By registering, shareholders will benefit from portfolio monitoring software that offers regular updates throughout the life of the case—a valuable resource for keeping track of developments.

The Role of The Gross Law Firm

The Gross Law Firm is recognized for its commitment to safeguarding investor rights across the nation. Their mission focuses on protecting those adversely affected by corporate misconduct, ensuring that businesses abide by ethical practices and good corporate citizenship. This class action suit aims to recover losses borne by investors as a result of any alleged fraudulent activities, misleading statements, or omissions that artificially inflated Cardlytics's stock value.

Contact Information

Interested shareholders should not hesitate to reach out to The Gross Law Firm. You can contact them via:

• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903
• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018

Participating in this class action is at no additional cost or obligation to you, making it a low-risk opportunity to potentially recover lost funds. Don't miss this chance to stand up for your financial rights as a Cardlytics shareholder.

For more information and to submit your claim, visit the official case submission page here. Act swiftly to ensure your interests are represented!